J&J's HIV Vaccine

Johnson & Johnson is preparing for a series of HIV vaccine trials

Johnson & Johnson Corporation (J&J) intends to start testing its vaccine against human immunodeficiency virus (HIV) in several countries. This was reported to TASS by the company's official representative Corina Ramers-Verhoeven.

As she explained, we are talking about the third phase of testing of an experimental drug that was developed by the pharmaceutical company Janssen based in Belgium, it is a subsidiary of J&J. These studies are planned to be conducted in the USA, Mexico, Peru, Argentina, Italy, Spain and Poland.

According to Ramers-Verhoeven, the company is currently sending regulatory requests to the relevant regulatory authorities in these countries. The representative of J&J noted that this will be the second J&J HIV vaccine at this stage of testing. Another one is being tested in five South African States.

Founded in 1886, Johnson & Johnson is one of the world's largest manufacturers of medicines, cosmetic and sanitary products, and medical equipment. In 2018, J&J's turnover was about $81 billion.

A number of countries, including Russia, are trying to create an effective and affordable HIV vaccine. In May 2018, representatives of the Joint United Nations Programme on HIV/AIDS (UNAIDS) stated that the development of such a vaccine would be a serious success in the fight against a deadly virus.

Portal "Eternal youth" http://vechnayamolodost.ru